Schlumberger M, Fragu P, Gardet P, Lumbroso J, Violot D, Parmentier C
Médicine Nucléaire, INSERM U66, Institut Gustave-Roussy, Villejuif, France.
Eur J Nucl Med. 1991;18(3):153-7. doi: 10.1007/BF02262724.
A new commercially available kit for thyroglobulin (Tg) measurement [immunoradiometric assay (IRMA) system based on monoclonal antibodies] was used in 479 patients with thyroid carcinoma. The effective working range was 1 ng/ml, and results were strongly correlated with our homemade radioimmunoassay (RIA). This IRMA method is less susceptible to interferences of auto-antibodies than our RIA. During thyroxine (T4) treatment, the Tg level was undetectable in 98% of patients after total thyroid ablation, in 91% after total thyroidectomy and in 42% after lobectomy only. In this situation, Tg was found in all patients with large metastases and in 88% of those with small metastases. Following T4 withdrawal, Tg was detectable in all patients with neoplastic disease and in 13% of those in complete remission after total thyroid ablation. In conclusion, Tg measured with this IRMA method appears to be a reliable marker of differentiated thyroid carcinoma.
一种新的可商购的甲状腺球蛋白（Tg）检测试剂盒[基于单克隆抗体的免疫放射分析（IRMA）系统]被用于479例甲状腺癌患者。有效工作范围为1 ng/ml，结果与我们自制的放射免疫分析（RIA）密切相关。与我们的RIA相比，这种IRMA方法更不易受到自身抗体的干扰。在甲状腺素（T4）治疗期间，98%的甲状腺全切除术后患者、91%的甲状腺全切术后患者以及仅行肺叶切除术后42%的患者中，Tg水平检测不到。在这种情况下，所有有大转移灶的患者以及88%有小转移灶的患者中都发现了Tg。停用T4后，所有肿瘤疾病患者以及甲状腺全切除术后完全缓解患者中的13%可检测到Tg。总之，用这种IRMA方法检测的Tg似乎是分化型甲状腺癌的可靠标志物。
